India, Dec. 10 -- Zydus Lifesciences has launched 'Zyrifa', a Denosumab biosimilar. Denosumab is a monoclonal antibody with several indications related to bone health, primarily in the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. This will provide access and treat patients with bone metastases due to breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumours. Metastases, is when the cancer spreads to the bones and other organs in the body indicating an advanced stage of cancer. 'Zyrifa' is priced at MRP of Rs 12,495.Speaking on this launch, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences, said 'With Denosumab 120 mg SC, we aim to bring access, affordabilit...